Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage

J Clin Oncol. 2009 Nov 20;27(33):e198-200. doi: 10.1200/JCO.2008.21.6473. Epub 2009 Oct 5.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged, 80 and over
  • Antineoplastic Agents, Alkylating / administration & dosage
  • Antineoplastic Agents, Alkylating / adverse effects
  • Catheterization, Central Venous / adverse effects
  • Device Removal
  • Dioxoles / administration & dosage
  • Dioxoles / adverse effects*
  • Drainage / methods
  • Extravasation of Diagnostic and Therapeutic Materials
  • Female
  • Follow-Up Studies
  • Humans
  • Immunohistochemistry
  • Infusions, Intravenous
  • Irritants / adverse effects*
  • Leiomyosarcoma / drug therapy*
  • Leiomyosarcoma / pathology
  • Necrosis / chemically induced
  • Necrosis / pathology
  • Necrosis / surgery
  • Severity of Illness Index
  • Skin Ulcer / chemically induced*
  • Skin Ulcer / pathology
  • Skin Ulcer / surgery
  • Soft Tissue Injuries / chemically induced*
  • Soft Tissue Injuries / physiopathology
  • Soft Tissue Injuries / surgery
  • Tetrahydroisoquinolines / administration & dosage
  • Tetrahydroisoquinolines / adverse effects*
  • Trabectedin
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Alkylating
  • Dioxoles
  • Irritants
  • Tetrahydroisoquinolines
  • Trabectedin